
Tranexamic Acid: Topical formulas are studied for melasma, with mixed results. Vitamin C: Some topical formulas modestly improve photodamaged skin and uneven tone.


Consider a topical pigment option; the evidence is mixed and formula-specific.
Choose for an optional antioxidant and modest photoaging benefits; formula stability matters.
Can you use both?
A popular pairing for dark spots and melasma.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Affects plasmin-related signaling: May reduce signals that stimulate pigment production. May help uneven pigmentation: Delivery and the formula influence topical results.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.

Helps limit oxidation: Ascorbic acid neutralizes reactive molecules. Supports collagen enzymes: It is a cofactor in collagen production.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Built from where each one usually sits in a routine. Introduce one at a time.
Topical tranexamic acid studies have used different delivery systems, including 1.8% liposomal lotion and 5% creams or solutions. Oral treatment and procedure-assisted delivery are separate medical decisions.
1.8%
5%
Studied liposomal lotion
One melasma trial tested this delivery system. Its percentage cannot be directly compared with an ordinary serum.
Studied topical formulas
Several melasma studies used topical formulas at this strength. Evidence does not establish one best concentration for all pigment concerns.
Choosing a strength: Look for evidence on the finished topical product. Do not use injectable or oral products as DIY skincare.
Higher strengths: A stronger topical percentage has not been shown to guarantee better results. Oral use requires separate evaluation of risks, including clotting risk.
Formula matters: Liposomal delivery, other brightening ingredients and procedures can change the treatment. A microneedling study is not evidence for the same result from a home serum.
Vitamin C percentages only make sense when the form is named. Human studies include 5% L-ascorbic acid cream and a 15% L-ascorbic acid antioxidant combination; derivatives are different ingredients.
5%
15%
20%
Studied L-ascorbic acid cream
A lower-strength finished cream studied for photoaged skin. A modest percentage can still have clinical evidence.
Studied antioxidant combination
Studied with vitamin E and ferulic acid. The result supports that combination, not vitamin C in every formula.
Absorption-study benchmark
A pig-skin study found maximal delivery at this concentration under its test conditions. It is not proof of the best clinical dose.
Choosing a strength: Check whether the product contains L-ascorbic acid or a derivative. Percentages of different forms are not interchangeable.
Higher strengths: A higher number is not automatically better and may be less comfortable. A laboratory delivery result is not a recommendation to maximize strength.
Formula matters: Acidity, stability, packaging and the other ingredients affect performance. A derivative serum cannot be ranked against L-ascorbic acid by percentage alone.
Approximate windows, not promises.
First few weeksAssess tolerance first; pigment change is usually slower.
First few weeksAssess tolerance and texture; immediate softness can come from the base formula.
4–8 weeksSome studied regimens begin showing pigment improvement.
4–8 weeksSubtle changes may appear in some tested products; evidence varies.
8–12 weeksA useful review point for benefit and irritation.
8–12 weeksCompare photographs in the same lighting and reassess benefit.
3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.
3–6 monthsPhotoaging trials often need several months; expect modest rather than dramatic change.
6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.
6–12 monthsLong-term evidence is limited for many cosmetic actives; continue only if useful.
Can sting or cause redness; do not substitute tablets or injections for a cosmetic product.
Acidic formulas may sting; stop for persistent redness or a rash.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.
Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.
Choose a simple formula and test a small area first. Individual tolerance matters more than an ingredient’s reputation for being gentle.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.
Melasma is common in pregnancy, so this comes up constantly. Oral tranexamic acid is not a casual pregnancy decision, and the topical version has little pregnancy-specific data. Ask the doctor managing your pregnancy, since they know your full picture.
Topical vitamin C is generally considered acceptable in pregnancy; check the complete formula with your clinician.
On the skin. The finished product delivers tranexamic acid in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. May affect plasmin-related signalling involved in pigmentation; a small molecular size does not guarantee delivery.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
On the skin. The finished product delivers vitamin c in a particular vehicle.
Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.
Conversion. No activation step is established as necessary for its intended topical role.
Skin response. Ascorbic acid participates in antioxidant and collagen pathways; stability and delivery limit topical performance.
Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.
Consider a topical pigment option; the evidence is mixed and formula-specific.
A small vehicle-controlled 5% trial did not show superiority over vehicle. A larger active-comparator study found improvement in both groups but did not prove equivalence to hydroquinone.
Choose for an optional antioxidant and modest photoaging benefits; formula stability matters.
Small controlled trials support specific formulas over three to six months. Derivatives have different masses and evidence; they cannot be assumed interchangeable with L-ascorbic acid.
Sources